Repository logoRepository logo
GRO
  • GRO.data
  • GRO.plan
Help
  • English
  • Deutsch
Log In
New user? Click here to register.Have you forgotten your password?
Publications
Researcher
Organizations
Other
  • Journals
  • Series
  • Events
  • Projects
  • Working Groups

Browsing by Author "Zender, Lars"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Results Per Page
  • Sort Options
  • Some of the metrics are blocked by your 
    consent settings
    Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression
    (2012)
    Schulz, Ramona
    ;
    Marchenko, Natalia D.
    ;
    Holembowski, Lena  
    ;
    Fingerle-Rowson, Günter
    ;
    Pesic, Marina
    ;
    Zender, Lars
    ;
    Dobbelstein, Matthias  
    ;
    Mol, Ute M.
  • Some of the metrics are blocked by your 
    consent settings
    Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression
    (Rockefeller Univ Press, 2012)
    Schulz, Ramona
    ;
    Marchenko, Natalia D.
    ;
    Holembowski, Lena  
    ;
    Fingerle-Rowson, Guenter
    ;
    Pesic, Marina
    ;
    Zender, Lars
    ;
    Dobbelstein, Matthias  
    ;
    Moll, Ute M.  
    Intracellular macrophage migration inhibitory factor (MIF) often becomes stabilized in human cancer cells. MIF can promote tumor cell survival, and elevated MIF protein correlates with tumor aggressiveness and poor prognosis. However, the molecular mechanism facilitating MIF stabilization in tumors is not understood. We show that the tumor-activated HSP90 chaperone complex protects MIF from degradation. Pharmacological inhibition of HSP90 activity, or siRNA-mediated knockdown of HSP90 or HDAC6, destabilizes MIF in a variety of human cancer cells. The HSP90-associated E3 ubiquitin ligase CHIP mediates the ensuing proteasome-dependent MIF degradation. Cancer cells contain constitutive endogenous MIF-HSP90 complexes. siRNA-mediated MIF knockdown inhibits proliferation and triggers apoptosis of cultured human cancer cells, whereas HSP90 inhibitor-induced apoptosis is overridden by ectopic MIF expression. In the ErbB2 transgenic model of human HER2-positive breast cancer, genetic ablation of MIF delays tumor progression and prolongs overall survival of mice. Systemic treatment with the HSP90 inhibitor 17AAG reduces MIF expression and blocks growth of MIF-expressing, but not MIF-deficient, tumors. Together, these findings identify MIF as a novel HSP90 client and suggest that HSP90 inhibitors inhibit ErbB2-driven breast tumor growth at least in part by destabilizing MIF.

About

About Us
FAQ
ORCID
End User Agreement
Privacy policy
Cookie consent
Imprint

Contact

Team GRO.publications
support-gro.publications@uni-goettingen.de
Matrix Chat: #support_gro_publications
Feedback

Göttingen Research Online

Göttingen Research Online bundles various services for Göttingen researchers:

GRO.data (research data repository)
GRO.plan (data management planning)
GRO.publications (publication data repository)
Logo Uni Göttingen
Logo Campus Göttingen
Logo SUB Göttingen
Logo eResearch Alliance

Except where otherwise noted, content on this site is licensed under a Creative Commons Attribution 4.0 International license.